Table 5 Internal consistency reliability of the FH KAP questionnaire
Item No | Area of KAP regarding FH | KR-20 | Overall KR-20 |
|---|---|---|---|
Knowledge domain | 0.79 | ||
3 | Description of FH | 0.53 | |
4 | Identification of lipid profile in FH | ||
6 | Prevalence of FH globally | ||
7 | Transmission of FH to first-degree relative | ||
8 | Rate of CAD risk in untreated FH | ||
9 | Age threshold for premature CAD | ||
11 | Genetic test for diagnosis of FH | ||
22 | Target LDL-c in FH | ||
23 | Important family history in FH | ||
24 | Exclusion of the diagnosis of FH | ||
25 | Management options in FH | ||
Awareness domain | Â | ||
1 | Familiarity with FH | 0.76 | |
2 | Awareness of NICE clinical guideline | ||
15 | Awareness of lipid specialist | ||
19 | Awareness of other FH clinical guidelines | ||
20 | Awareness of FH diagnostic criteria | ||
Practice domain | Â | ||
5 | Assistance in detection of FH | 0.61 | |
10 | Screening for FH in premature CAD | ||
12 | Family screening in FH patients | ||
13 | Most effective healthcare provider to detect FH and screen first-degree relatives | ||
14 | Age of FH screening among young person | ||
17 | Pharmacotherapy used for hypercholesterolaemia | ||
18 | Combined pharmacotherapy used for severe hypercholesterolaemia | ||
21 | CAD risk stratification in FH | ||